• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Allogeneic Bone Marrow Transplantation (BMT) for Indications Other Than Aplastic Anemia and Leukemia
【24h】

Allogeneic Bone Marrow Transplantation (BMT) for Indications Other Than Aplastic Anemia and Leukemia

机译：同种异体骨髓移植（BmT）用于再生障碍性贫血和白血病以外的适应症

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Allogeneic bone marrow transplantation is a technique in which a portion of the marrow from an HLA matched donor is infused into a recipient who has a marrow deficiency. The purpose is to restore normal marrow function. Bone marrow transplants have now been successfully applied as curative approaches to the treatment of a series of lethal congenital disorders of the hematopoietic system. It offers promise in the treatment of certain genetic disorders of metabolism. Application of marrow transplants early in the course of many of these diseases offers the highest likelihood of success with the lowest incidence of morbidity and mortality. BMT has been firmly established as the treatment of choice for SCID and Wiscott-Aldrich Syndrome. However, the considerable risks of morbidity and mortality associated with marrow transplants has limited the consideration of this technology for chronic genetic diseases to those that are fatal rather than merely disabling. More data must be generated to determine if BMT should be accepted as an established rather than an experimental treatment. Up to the present, BMT has only been employed occasionally in treating malignancies other than leukemias and its role for non-leukemia tumors awaits better definition of tumor types and stages that might respond to this strategy.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号